ArticleAnnals of clinical and translational neurology2026
Bi- and Mono-Allelic RFC1 Expansion in a North American Cohort With Idiopathic Axonal Neuropathy.
Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveRFC1 biallelic repeat expansion is increasingly recognized as a cause of chronic idiopathic axonal polyneuropathy (CIAP), but it remains challenging to know who to test. This study aims to determine the prevalence of biallelic and monoallelic RFC1 expansions and their corresponding neuropathy phenotypes in CIAP patients and identify discriminators of RFC1 expansion status.
methodsThe cross-sectional Peripheral Neuropathy Research Registry was queried for individuals with CIAP and tested for RFC1 expansions. Associations between RFC1 biallelic and monoallelic status and clinical history, neurologic examination findings, fiber type involvement (exam-based), electrodiagnostic (EDX) patterns (sensory, sensorimotor, motor), and the presence of sensory neuronopathy (Camdessanche criteria) were determined.
resultsA total of 788 participants were enrolled in the study, of whom 18 had biallelic RFC1 expansions (2.3%) and 62 had monoallelic RFC1 expansions (7.9%). All biallelic RFC1 patients had a mixed fiber neuropathy, 27.8% had weakness on examination, and 44.4% had motor EDX abnormalities. Our study identified five factors associated with RFC1 biallelic status: (1) abnormal upper limb vibration (OR 4.65, 95% CI 1.20-18.13), (2) abnormal sensory EDX studies (OR 4.65, 95% CI 1.11-24.29), (3) sensory-only polyneuropathy on EDX (OR 7.17, 95% CI 1.69-38.15), (4) sensory neuronopathy (OR 3.64, 95% CI 1.16-11.19) (AUCs = 0.80-0.81 for biallelic and 0.69-0.71 for monoallelic), and (5) body mass index (OR 0.88, 95% CI 0.78-0.97).
interpretationThe prevalence of biallelic RFC1 expansion is lower in this North American CIAP population compared to previous studies. Motor involvement was frequent. Discrimination of biallelic status was good, but poor for monoallelic status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.